Table 3.

Association of polypharmacy with adverse outcomes at 3 months

	Prevalence N event/group (%)	Crude odds ratio (95% CI)	Adjusted odds ratio† (95% CI)	Adjusted odds ratio* (95% CI)	Adjusted odds ratio◊ (95% CI)
Mortality 3 months
Total population	76/832 (9)
Non-polypharmacy	14/323 (4)	Reference	Reference	Reference
Polypharmacy	39/360 (11)	2.68 (1.43–5.04)	2.62 (1.39–4.93)	2.10 (1.10–4.00)	1.80 (0.92–3.52)
Excessive polypharmacy	23/149 (15)	4.03 (2.01–8.08)	3.92 (1.95–7.90)	2.40 (1.15–5.02)	2.32 (1.10–4.90)
Additional odds per 1 medication		1.14 (1.08–1.20)	1.14 (1.08–1.20)	1.10 (1.04–1.16)	1.10 (1.03–1.17)
Readmission 3 months
Total population	249/833 (30)
Non-polypharmacy	83/335 (25)	Reference	Reference	Reference
Polypharmacy	121/367 (33)	1.46 (1.05–2.04)	1.46 (1.04–2.04)	1.32 (0.94–1.86)	1.25 (0.87–1.90)
Excessive polypharmacy	47/148 (32)	1.37 (0.89–2.10)	1.30 (0.84–1.20)	1.04 (0.66–1.64)	0.97 (0.60–1.56)
Additional odds per 1 medication		1.05 (1.02–1.09)	1.05 (1.01–1.09)	1.03 (0.99–1.07)	1.02 (0.98–1.07)
Fall 3 months
Total population	141/683 (21)
Non-polypharmacy	45/285 (16)	Reference	Reference	Reference	Reference
Polypharmacy	68/300 (23)	1.59 (1.04–2.41)	1.45 (0.97–2.27)	1.30 (0.84–2.00)	1.28 (0.82–2.01)
Excessive polypharmacy	28/111 (25)	1.76 (1.03–3.01)	1.71 (0.99–2.93)	1.28 (0.73–2.26)	1.31 (0.74–2.35)
Additional odds per 1 medication		1.05 (1.00–1.10)	1.05 (1.00–1.10)	1.03 (0.97–1.08)	1.02 (0.97–1.08)

^† Adjusted for age, gender, * adjusted for age, gender, ISAR-HP score, ◊ adjusted for age, gender, CCI